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Abstract
With the goal of identifying splicing alterations in myotonic dystrophy 1 (DM1) tissues that may yield insights into targets or
mechanisms, we have surveyed mis-splicing events in three systems using a RT-PCR screening and validation platform. First,
a transgenic mouse model expressing CUG-repeats identified splicing alterations shared with other mouse models of DM1.
Second, using cell cultures from human embryonic muscle, we noted that DM1-associated splicing alterations were
significantly enriched in cytoskeleton (e.g. SORBS1, TACC2, TTN, ACTN1 and DMD) and channel (e.g. KCND3 and TRPM4)
genes. Third, of the splicing alterations occurring in adult DM1 tissues, one produced a dominant negative variant of the
splicing regulator RBFOX1. Notably, half of the splicing events controlled by MBNL1 were co-regulated by RBFOX1, and
several events in this category were mis-spliced in DM1 tissues. Our results suggest that reduced RBFOX1 activity in DM1
tissues may amplify several of the splicing alterations caused by the deficiency in MBNL1.
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Introduction
Myotonic dystrophy type 1 (DM1) is a multisystem disorder that
affects primarily skeletal muscles causing myotonia, muscle
weakness and degeneration, but also causes impaired heart
function, ocular cataracts and various dysfunctions of the central
nervous system. DM1 is caused by the expansion of CTG-
trinucleotide repeats in the 39-untranslated region (UTR) of the
DMPK gene. The most commonly accepted mechanistic expla-
nation for this disease is that the nuclear accumulation of
transcripts containing CUG expansions sequesters the RNA
binding protein MBNL1 and stabilizes the CELF family member
CUGBP1 through hyperphosphorylation [1–6]. The disregulated
expression and activity of these RNA binding proteins in DM1
individuals leads to perturbations in the alternative splicing
program of key genes, such that many are switched to their
embryonic profiles [2,7]. Among the mis-splicing events that have
been documented [8], splicing reversions occurring in the muscle
chloride channel CLCN1 [9,10], the insulin receptor INSR [11]
and BIN1 [12] contribute respectively to myotonia, insulin
resistance and muscle weakness. Since MBNL1 has also been
implicated in transcription and other aspects of RNA biogenesis
[13–15], and since CUGBP1 can regulate translation [16,17],
other defects in gene expression are expected. Moreover, the CUG
repeat expansion may have other effects on gene expression, as
suggested by a study in a CTG repeat-expressing mouse that
identified changes in the abundance of many extracellular matrix
mRNAs [14]. In addition to MBNL1 and CUGBP1, the RNA
binding proteins hnRNP H and MBNL2 have also been
implicated in DM1 pathogenesis [4,14,18–21].
While the full spectrum of splicing alterations in DM patients
remains to be determined, a variety of model systems have been
used to study these alterations and determine the contributions
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that CUG repeats, MBNL downregulation, and CUGBP1
overexpression have to disease evolution [8]. Modeling trinucle-
otide repeat instability in transgenic mice has allowed the
recapitulation of human splicing defects in a few orthologous
murine genes [14,22], and the replication of some of the muscle
phenotypes and histopathology of human DM1 [23–25]. Notably,
MBNL1 knockout mice display myotonia due to abnormal
CLCN1 splicing and develop myopathy, but exhibit no sign of
muscle degeneration [26]. On the other hand, induced expression
of CUGBP1 in adult skeletal muscle or the heart also mimics DM1
histopathology [27,28]. Microarray analysis has identified mis-
splicing events in the skeletal muscle of the HSALR mouse (FVB/n
strain) that expresses approximately 250 CUG-repeats [14].
Comparing its splicing profile with that of MBNL1 knockout
mice revealed that 128 of a total of 172 mis-splicing events were
common to both mouse models. Thirty-three of these were
validated by RT-PCR and three were confirmed to be mis-spliced
in the majority or all human samples tested [14].
To reveal splicing alterations that may be relevant to the DM1
phenotypes, we deployed our RT-PCR screening platform to
identify which mis-splicing events documented in the HSALR and
MBNL1 knockout mice (FBV/n strain) were similarly altered in
mice (C57BL6/129/OLA/FVB strain) displaying a milder DM1
phenotype. We also used the platform to identify muscle-relevant
mis-splices in myoblast cell cultures derived from embryonic and
adult DM1 tissues. Because one of the DM1 mis-splicing events
identified in adult DM1 tissues occurred in the gene encoding the
splicing regulator RBFOX1, we further explored the regulatory
interconnections between MBNL1 and RBFOX1, and discovered
that these RNA binding proteins cooperate to regulate many
muscle-relevant genes, a subset of which are mis-spliced in DM1.
Materials and Methods
The study has been approved by the Ethics Committee of
CRCHU de Quebec (project A12-08-1019). Human tissues and
cells were obtained from the MyoBank-CHUQ, which has been
approved by the Ethics Committee of the CRCHU de Quebec
(project A12-08-1022). Anesthesia of mice was done with 2%
isoflurane, CO2 followed by cervical dislocation. The protocol was
approved by the CRCHU de Quebec institutional Animal Care,
the ‘‘comite´ de protection des animaux du CHUQ’’ (CPAC,
protocol No 2103151-1).
Mouse, human cell lines and tissues
Mice carrying the CUG600 repeats are described in [29]. Mice
carrying the CUG1200 repeats are called DMSXL and are
described in [30]. Human normal satellite muscle cells were
derived from quadriceps muscle biopsy of 41 and 47 year old
females. Human fetal normal satellite muscle cells (HFN) were
derived from a 15 week old fetus. Human DM1 satellite muscle
cells carrying 750 CTG repeats (ST-750), were derived from a 20
week old fetus. Human DM1 satellite muscle cells carrying 1200
CTG (ST-1200) and 3500 (ST-3500), were derived from a 13 and
a 15 week old fetus. Human muscle satellite cells were grown in
MB-1 medium supplemented with 15% heat-inactivated fetal
bovine serum, 5 mg/ml insulin, 0.5 mg/ml BSA, 10 ng/ml
epidermal growth factor and 0.39 mg/ml dexamethasone (prolif-
erative medium), as previously described [31,32]. For human
muscle satellite cell differentiation, the cells were subsequently
transferred to DMEM supplemented with 0.5% heat-inactivated
fetal bovine serum,10 mg/ml insulin and 10 mg/ml apo-transferrin
(differentiation medium). All cultures were incubated at 37uC in a
humid atmosphere containing 5% CO2. Normal and DM1 cells
were used between the 4th and 6th passages. The number of
passages refers to the total number of passages from the time
following the isolation of the initial satellite muscle cell population
from the fetus. DM1 skeletal muscle samples were obtained from
the left biceps brachii of 3 females aged 44, 45 and 48 years old
and two males, aged 31 and 40 years old. All donors had an adult
form of the disease. Normal skeletal muscle samples were obtained
from 3 males aged 32, 41 and 48 years old and one 41 years old
female. Biopsies were done during surgical intervention. All
human DM1 muscle cell lines and DM1 tissues were obtained
from the Quebec DM1 biobank, following consent from the
CHUQ ethical committee
RNA interference assay with siRNAs. The siRNAs used to
knockdown the expression of RNA-binding proteins were
purchased from IDT (Coralville, Iowa) siRNA target sequences
were GACGCAAUAACUUGAUUCAdTdT (MBNL1) and
GGUCUCGUUCUUUCUUCAUdTdT (RBFOX1). siRNAs du-
plexes carrying dTdT 39 overhangs were transfected into cells at a
concentration of 100 nM using Lipofectamine 2000 (Invitrogen).
RNA was extracted 48 hours post-transfection. Knockdown was
validated by evaluating relative expression levels by SYBR green
based RT-qPCR as previously described [33,34]. Primer sequenc-
es for target and reference genes are listed in Table S2, qPCR
tab.
RT-PCR assays
Our collection of alternative splicing units was derived from the
RefSeq database. Sets of primers mapping in the exons flanking all
the simple alternative splicing events were designed using Primer3
with default parameters. Total RNA was extracted using TRIzol
and quantified using a 2100 Bioanalyzer (Agilent Inc. Santa Clara,
CA, USA). A total of 2 mg of RNA was reverse transcribed using a
mix of random hexamers and oligo(dT) and the Omniscript
reverse transcriptase (Qiagen, Germantown, MD, USA) in a final
volume of 20 ml. Twenty ng of cDNA were amplified with 0.2 U/
10 ml of HotStarTaq DNA Polymerase (Qiagen) in the buffer
provided by the manufacturer, and in the presence of the specific
primers (IDT) for each splicing unit (at concentrations ranging
from 0.3 to 0.6 mM) and dNTPs. The list of ASEs, oligos, and
expected size of RT-PCR products are shown in Table S2), and
primer locations mapped to the UCSC genome browser can be
viewed at http://palace.lgfus.ca/data/related/2073/odgene_/.
When more than one ASE was targeted per gene, lowercase
letter suffixes were appended to gene names, e.g Dnm1l.a,
Dnm1l.b, …, see Tables S1 and S2 and link above for precise
locations. Reactions were carried out in the GeneAmp PCR
system 9700 (Applied Biosystems, Foster City, CA, USA). A first
cycle of 15 minutes at 95uC was followed by 35 cycles of
30 seconds at 94uC, 30 seconds at 55uC and 1 minute at 72uC.
Thermocycling was concluded with an extension step of 10 min-
utes at 72uC. Visualization and analysis of amplified products were
done using the LabChip HT DNA assay on a Caliper LC-90
automated microfluidic station (Caliper, Hopkinton, MA, USA).
Results
Splicing defects in mouse expressing CUG-repeats
The transgenic C57BL/6-derived mouse strains express 600
and 1200 CUG-repeats, and display phenotypic traits that are
characteristic of DM1 [25], but in a milder form compared to the
MBNL1 knockout and HSALR mice [30]. It was therefore of
interest to determine to what extent splicing alterations overlap
with the splicing alterations observed in the other CUG-expressing
HSALR mouse model (FVB/n strain) [14].
Splicing Regulation in DM1
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Total RNA from two muscle sources (tibialis anterior and
gastrocnemius) were isolated from three normal mice, two DM1
mice expressing 600 repeats (CUG600) and three DM1 mice
expressing 1200 repeats (CUG1200). We used our RT-PCR
analysis platform [35–37] to interrogate a total of 172 alternative
splicing events (ASEs) in genes reported to be susceptible to
changes in HSALR and MBNL knockout mice [14]. Because our
RT-PCR approach requires the design of primers on either side of
each splicing event, only 58 of the 172 ASEs, representing cassette
exons, and alternative 59 and 39 splice sites could be designed
directly. The remaining reported ASEs, comprised mostly of
microarray-identified alternate transcript start and end sites, were
not directly accessible by our RT-PCR technique. Nonetheless, we
were able to identify and design primers for 114 additional ASEs
in regions overlapping these affected transcripts. Maps of the 172
ASEs analyzed showing our primer designs and the regions
reported by Du et al. [14] can be viewed at http://palace.lgfus.ca/
data/related/2080/odgene_/. RT-PCR amplifications followed
by microcapillary electrophoretic separation were designed to
detect a long and a short isoform of unambiguous identity. For
each ASE, the percent spliced-in (PSI or Y) value, defined as the
ratio between the concentration of the long isoform over the sum
of the short and long isoform concentrations, was computed.
When more than two amplification products were observed, the
short and long products were selected to maximize their total
abundance across the reaction set. To assess the significance of our
results, we used a statistical approach tailored for the analysis of
genomic data based on the false discovery rate (FDR) expressed as
a q-value [38]. For example, a 5% FDR, q#0.05, indicates that
5% of the results judged to be significant could represent false
positive signals. In addition, to improve the functional significance
of our hits, we only considered absolute PSI value differences,
|DY|, that were superior to 5 percentage points.
Although each tissue for each mouse was analyzed individually,
the results of the two tissues for each mouse were pooled in the
final analysis because very few differences were noted between
tissues (see below). Based on the above criteria, a total of 24 ASEs
were identified as significantly misregulated in CUG1200 mice
(Fig. 1, Table S1). From the set of 58 directly designed ASEs, 9
were in agreement with the misregulated events in the HSALR
Figure 1. Splicing defects in a mouse strain expressing CUG repeats. Total RNA from muscle tissues of transgenic C57BL6 mice expressing
600 and 1200 CUG-repeats were screened for alternative splicing defects. We interrogated 172 ASEs in genes reported to be susceptible to changes in
HSALR and MBNL knockout mice [14]. Using a false discovery rate threshold (q-value) of 0.05 and |DY| greater than 5 percentage points, we identified
24 ASEs in CUG1200 (black bars) that are significantly different from WT (white bars). Changes that were also significant in CUG600 (grey bars) are
indicated with an asterisk. Results are presented in histograms by order of significance based on q-values.
doi:10.1371/journal.pone.0107324.g001
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Figure 2. Differences in alternative splicing events (ASEs) when normal adult muscle cell lines are compared to normal embryonic
muscle cell lines. (A–C) A. Histograms representing the four ASEs (ABCB8, C10orf58, ACTN1, ENO3) that are differentially spliced when normal
embryonic cell lines (white bars) are compared to normal adult cell lines (black bars). B. Venn diagram representing hits when the three embryonic
cell line categories (ST-750, ST-1200, and ST-3500) were compared to normal fetal cell lines. C. Histograms representing Y values in the normal fetal
(white bars), ST-750 (light grey bars), ST-1200 (dark grey bars) and ST-3500 cells (black bars). Only the top 27 of the 50 splicing alterations seen in ST-
3500 (q # 0.05) are shown which also include all ST-750 ({) and ST-1200 (*) hits (respective q#0.05) relative to normal fetal cells.
doi:10.1371/journal.pone.0107324.g002
Splicing Regulation in DM1
PLOS ONE | www.plosone.org 4 September 2014 | Volume 9 | Issue 9 | e107324
Figure 3. Splicing defects in DM1 patient tissues. (A–B) A. Y values for ten misspliced ASEs are represented as histograms for 4 adult controls
(white bars) and 5 DM1 patients (black bars). Error bars represent standard deviations for each ASE. Hits were defined as changes displaying q values
,0.05 and |DY|.5%. B. Sample UCSC Genome Browser (http://genome.ucsc.edu) adaptation showing the chromosome 19 region harboring human
insulin receptor, INSR. Top image shows reported full-length RefSeq transcripts, the targeted ASE is boxed and shown in detail in the bottom image.
The positions and names of the primers used for mRNA amplification by RT-PCR are shown above the transcripts. Links to transcript maps and primer
positions for all human ASEs studied here can be found at http://palace.lgfus.ca/data/related/2073/odgene_/.
doi:10.1371/journal.pone.0107324.g003
Splicing Regulation in DM1
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mouse, and 4 shifted in the opposite direction [14]. The remaining
11 misregulated ASEs were identified from the 114 indirectly
designed ASEs, i.e. occurring in the same genes and overlapping
regions reported in the HSRLA study (Table S1). Three of the
misregulated ASEs (Erc1, Rpn2.a and Usp5) were also signifi-
cantly altered in CUG600 mice (marked with a * in Fig. 1). Other
ASEs in the CUG600 samples had mean Y values consistent with
a slight progression in the direction of the shift occurring in
CUG1200 (e.g. Mknk2, Mtdh, Dnm1l.a, Ldb3b, Gnas, Ptpmt1.b
and Zmiz2). The splicing profiles between tibialis anterior and
gastrocnemius were very similar except for 5 ASEs (Mtdh.a, Opa1,
Picalm.b, Spag9 and Smyd1) (Table S1). Of these, only Smyd1
was mis-spliced in CUG600/1200 hits. Of the ensemble of
CUG1200 hits, Usp5 and Drap1 shifted in the DMBNL, but not
in the HSALR mice based on microarray analysis [14]. The most
dramatic shifts occurred in Mtap1 and Drap1, with a greater than
20 point drop in exon inclusion in CUG1200 mice (Fig. 1).
DRAP1 is a transcription factor that can interact with FEZ1, a
protein involved in axon growth in nematodes [39]. Mtap1, also
known as MAP1B, encodes the microtubule associated protein 1b
involved in the cross-bridging between microtubules and other
cytoskeletal elements in neurons, and can interact with actin and
signaling proteins [40]. Interestingly, CTG repeats disturb the
expression and subcellular distribution of the related and
interacting partner MAP1A in a neuronal cellular model [41],
suggesting that the change in MAP1B splice variants may
contribute to this redistribution.
Mis-splicing events in human embryonic DM1 myoblast
primary cultures
More than 50 splicing alterations have been identified in skeletal
and cardiac muscle of adult humans suffering from DM1
[8,14,42]. Overall, the defects indicate an incapacity to engage
in a postnatal splicing transition [2,22]. To address the extent of
defective alternative splicing regulation in the developing muscle of
DM1 embryos, we produced human DM1 myoblastic primary
cultures from embryonic muscle tissues carrying 750, 1200 and
3500 CUG repeats (ST-750, ST-1200 and ST-3500, respectively).
Three cultures were produced from each original sample. Normal
embryonic and adult muscle cultures were also produced and used
as controls.
A detection screen using pooled RNA from normal and DM1
cultures was first carried out to identify splice variants for which
the less abundant form represented at least 10% of the sum of both
variants. Out of 2034 known human ASEs in muscle-relevant
genes, we identified 487 such ASEs. We used this set first to
compare myoblast cultures from normal adult and normal
embryonic muscles (3 cultures each). A T-test on these two sample
sets revealed fifty statistically significant ASEs, p,0.05 (Table S2,
DM1 fetal cells tab, column W). Of these, the top four events
that differentiate normal embryonic from normal adult muscle
primary myoblastic cultures were ABCB8, C10orf58, ACTN1 and
ENO3 (Fig. 2a).
Next, comparing splicing in DM1 and normal embryonic
primary cultures identified 50 ASEs that were differently spliced
between the embryonic ST-3500 and the normal embryonic
cultures (q ,0.05 and |DY| .5 percentage points) (Table S2,
DM1 fetal cells tab, columns B and T, Fig. 2b and 2c). For
6 of these, PDLIM3, SMTN, TACC2, BIN1.b, PPP1R12B and
SORBS1.c, the defects suggested an exacerbated embryonic
splicing profile. The ST-1200 cultures yielded 29 hits, 11 of them
seen in ST-3500 and displaying a good correlation between the
amplitude of the splicing alterations and the number of repeats in
the expansion (Fig. 2b and 2c, Table S2, DM1 fetal cells
tab, column R). The ST-750 myoblasts only produced 4 hits,
three of them occurring either in the ST-1200, ST-3500 or both
(TACC2) (Fig. 2b and 2c, Table S2, DM1 fetal cells tab,
column P). While all the differences noted were statistically
Figure 4. Role of MBNL1 and RBFOX1 in splicing regulation. (A–C) A. Venn diagram representing the overlap of hits obtained by knocking
down MBNL1 and RBFOX1 in the HFN embryonic muscle cell line. In panels B and C, Venn diagrams are presented to illustrate events coregulated by
MBNL1 and RBFOX1 that are mis-spliced in embryonic DM1 lines or and DM1 adult samples. The number and identity of the ASEs in each category
are indicated. Gene names in bold indicate that the splicing shift for those ASEs occur in the reverse direction to the DM1 mis-splice.
doi:10.1371/journal.pone.0107324.g004
Splicing Regulation in DM1
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significant, a subset in each category (e.g., the ASEs affected in ST-
750 but not in ST-3500) may reflect individual-specific splicing
differences or differences in the status of embryonic muscle
differentiation at the time of collection. Thus, because some of the
splicing differences may reflect genetic differences between the
individuals, splicing differences that are common to ST-3500 and
ST-1200 are likely to be most relevant to DM1.
On the other hand, we observed more alterations in the ST-
3500 samples, which is what would be expected. Of the 50 muscle-
relevant, statistically significant alternative splicing aberrations in
the ST-3500 myoblast cultures, one mis-splicing event in BIN1
(exon 11) associates with T tubule alterations and muscle weakness
in myotonic dystrophy [12] (Fig. 2c). Exon 11 skipping in the
insulin receptor (INSR) is one of the first alternative splicing events
described to be aberrant in DM1 patients [11]. Although INSR
splicing was aberrant in the embryonic ST-3500 cell lines
(Fig. 2c), it occurred in the direction opposite to adult DM1
(i.e., more inclusion in fetal DM1 and more skipping in adult
DM1).
Since the 487 ASEs that were screened were selected for their
relevance to muscle function, splicing differences may affect
muscle function. Functional gene ontology annotation using
GOrilla [43] revealed a greater than 3-fold enrichment for
processes related to cytoskeleton and actin-linked cytoskeleton
function (p values of 3.461024 and 9.261024, respectively), as
well as a 2.5-fold enrichment for cytoskeleton, as a cellular
compartment. The cytoskeleton-related genes in these lists were
SYNE1, APC, MEF2A, OBSL1, TTN, PDLIM3, NF1, TACC2,
ACTN1, SORBS1, DMD, SLMAP, TPM3, ANK2, BIN1 and
FLNC. The enrichment is even stronger if we include MEF2D
[44] and the cytoskeleton-associated protein SMTN (smoothe-
lin)[45]. We also noted splicing alterations in several channel genes
including the transient receptor potential cation channel TRPM4,
the sodium channel SCN9A, the chloride channel CLCC1, the
voltage-gated potassium channel Kv4.3 gene KCND3, and the
voltage-dependent calcium channel CACNA1C. In the case of
CACNA1C, the variant made in DM1 cells changes the kinetics
and voltage-dependence of inactivation as well as recovery from
inactivation [46].
Altered splicing in human adult DM1 tissues
Next, we asked whether any of the splicing alterations identified
in DM1 fetal cultures also occurred in adult DM1 tissues. Using
five adult DM1 and four normal tissues, we selected 163 ASEs
based on q values (less than 0.1) for any of the previous 5
comparisons: fetal vs. ST-750, fetal vs. ST-1200, fetal vs. ST-3500,
fetal vs. combined ST-750, ST-1200 and ST-3500 and fetal vs.
adult. Following the analysis on adult tissues, we identified 10
Table 1. Alternative splicing events co-regulated by MBNL1 and RBFOX1.
Gene Description Function Association with diseases
Neuromuscular Organogenesis
CHRNG acetylcholin reeceptor c-subunit neuromuscular junction
CHRNA5 acetylcholine receptor neuromuscular junction
ACHE acetylcholinesterase neuromuscular junction
ILK integrin-linked kinase neuromuscular junction
EVC transmembrane muscle development Ellis-van Creveld syndrome
Channels
RYR1 (2) calcium release channel connects sarcoplasmic reticulum with tubules minicore myopathy
CLCN2 chloride channel epilepsy
CACNA1C calcium channel
KCNK2 potassium channel
TRPM4 calcium transport
CATSPER3 calcium channel
Others
JPH4 junctophilin plasma membrane and sarcoplasmic reticulum
NEB nebulin cytoskeletal matrix in sarcomeres nemaline myopathy
BMP4 TGF-b superfamily bone morphogenesis
CAPN3 calpain 3 putative protease that binds to titin limb-girdle muscular dystrophies type
2A
TAZ membrane associated cardiomyopathy
SYNE1 spectrin-repeat containing protein nuclear membrane Emery–Dreifuss muscular dystrophy
MYLK myosin light chain kinase
PHKB phosphorylase kinase
TBC1D1 cell differentiation
SORBS2 sorbin, tyrosine kinase assembly of signalling complex in stress fibers
MDH2 malate dehydrogenase
ITPR1 intracellular receptor for inositol 1,4,5-trisphosphate spinocerebellar ataxia
Genes in bold are mis-spliced in DM1 tissues.
doi:10.1371/journal.pone.0107324.t001
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events altered in DM1 with |DY| and q values of 5 percentage
points and ,0.05, respectively (Fig. 3, Table S2, DM1 tissues
tab). Of these, 6 were aberrantly spliced in the fetal DM1 cultures
(INSR, TTN.a, SORBS1.c, KCND3, SYNE1.b and QK1.a). The
exon inclusion event in a titin family member (TTN.a) occurs at
the 39 end of the coding region [47], as similarly noted in all fetal
DM1 cell lines. For INSR, SYNE1.b and QK1.a, splicing in DM1
adult tissues occurred in the direction opposite to the shift seen in
embryonic DM1 cultures. Although ITGA7, A2BP1, USP5 and
QK1.b were slightly below our cut-off in the fetal DM1 cultures,
A2BP1 and USP5 were hits in DM1 mouse models [14]. ITGA7
encodes an integrin that plays a role in acetylcholine receptor
clustering when neuromuscular junctions are formed [48]. We also
considered the next 20 strongest mis-spliced events in adult DM1
tissues (Table S2, DM1 tissues tab, blue coloring in
column E). Seven hits in this category were also seen as fetal
DM1 hits (ANK2.c, TRPM4.b, CLCC1.c, SORBS1.a, TRPM4.c,
MGEA5.a and CAST; the three underlined events shift in the
opposite direction of fetal DM1). Overall, 21% of the 30 adult
DM1 hits were also hits in the embryonic DM1 cell cultures.
Events that shifted in the same direction may reflect a DM1 fetal
splicing profile in the regenerating fibers of adult DM1 tissues [49].
Thus, although some splicing defects are common in embryonic
and adult muscle, others reflect embryonic- and adult-specific
splicing alterations.
MBNL1 and RBFOX1 co-regulate a subset of events
altered in DM1
To assess the contribution of the regulatory splicing factor
MBNL1 to the human DM1 splicing alterations, we knocked
down MBNL1 by RNA interference in a normal muscle
embryonic cell culture (HFN) and performed the splicing analysis
in triplicate. The depletions were confirmed by RT-qPCR (Table
S2, qPCR tab). We interrogated the 163 ASEs used in the
previous section, and identified 48 that were regulated by MBNL1
(Table S2, MBNL1 RBFOX1 knockdown tab, Fig. 4a).
Eleven of the MBNL1-responsive events were mis-spliced in the
DM1 embryonic cultures, five of them shifting in the direction
opposite to DM1 (Fig. 4b). The MBNL1 depletion affected only
one of our 10 strongest adult DM1 mis-splicing events, and 6 of
the 20 successive alterations (Blue colored hits in Table S2, DM1
tissues tab, column E, and Fig. 4c). These 7 shifts occurred
in the same direction in DMBNL1 and DM1 tissues.
Alternative splicing of A2BP1 (a.k.a. RBFOX1) was affected in
DM1 adult tissues (|DY|= 15 percentage points, q=0.04)
(Fig. 3a). In the DM1 fetal culture, it yielded a |DY| of 10
points, but with a q value above our threshold (0.08). Although not
a hit with the CUG1200 mice, the A2BP1 gene is mis-spliced in
the DMBNL1 mice [14]. In all cases, a skipping event produces a
variant that lacks a portion of the RNA recognition motif (RRM)
domain involved in recognizing the regulatory sequence (U/A)G-
CAUG [50–54]. RBFOX1 is specifically expressed in neurons,
heart and muscle [52,55]. RBFOX proteins are important
regulators of muscle function in zebrafish where their depletion
affects myofiber development [56]. RBFOX1 regulates the
alternative splicing of many critical transcripts essential for
neuronal excitation and synaptic transmission [57]. We asked if
RBFOX1 regulates the splicing of muscle-relevant genes.
Performing the depletion of RBFOX1 in the normal HFN culture
(in triplicate) revealed 34 splicing events that were sensitive to a
decrease in RBFOX1 (50% drop based on qRT-PCR) (Fig. 4;
Table S2 qPCR tab). Although it is unclear if the 10–15%
increase in the RBFOX1DRRM variant occurring in DM1 tissues
would be sufficient to alter the splicing regulation of target ASEs,
some impact may be expected because this variant displays
dominant negative activity [54]. Consistent with this view, 5 of the
34 RBFOX1-sensitive events were misregulated in embryonic
DM1 cultures (CAMK2G, TCF7L2, TRPM4.b, TRMP4.c and
CHRNG), and 4 were affected in adult DM1 (RYR, SYNE1.a,
TRMP4.b and TRMP4.c). Strikingly, half of the 48 events
regulated by MBNL1 were also regulated by RBFOX1 (Fig. 4a).
Moreover, 5 of 9 RBFOX1 hits that were mis-spliced in DM1
were also regulated by MBNL1 (Fig. 4b and 4c). We confirmed
this overlapping regulation by repeating the RBFOX and MBNL1
depletions in a different HFN cell culture. Even with partial
depletions, as judged by western analysis (Fig. S1a), 11 of 13
events that were regulated by MBNL1 were sensitive to the
depletion of RBFOX (Fig. S1b).
Discussion
Mouse model systems have been developed to reproduce the
molecular and physiopathological deficiencies found in DM1
patients. Although none of the current models displays the full
repertoire of physiological deficiencies observed in DM1 patients,
they nevertheless offer the possibility of associating specific
phenotypes with molecular alterations, and identifying discerning
features that might explain shared or specific defects. The Ares
group previously identified a collection of splicing alterations in
MBNL1 knockout mice and HSALR mice that express CUG-
repeats [14]. Of these, 4 of the 6 human orthologous ASEs were
affected in three DM1 individuals. Of the 11 orthologous ASEs
derived from hits reported in the Ares study, we found 4 (USP5,
TACC2, CAMK2 and A2BP1) that were affected in 9 embryonic
myoblast cell cultures and 5 adult patient muscle tissues. Using a
stringent set of criteria for revealing splicing alterations in muscle
tissues (splicing shifts greater than 5 percentage points and q#
0.05), only 5 of the 33 original validated mouse hits uncovered in
the Ares study were similarly mis-spliced in our CUG1200 mice.
Although the smaller set of molecular alterations that we identified
may be attributable to differences in the detection methods,
different levels of transgene expression likely contributed to the
discrepancies. Indeed, the CUG repeats of the CUG1200 mice are
imbedded in a transgenic DMPK gene whose expression level in
muscle is five times lower than the murine endogenous gene [30],
whereas the transcript carrying the 250 CUG repeats of the
HSALR mice is expressed at a much higher level [24]. Consistent
with this view, CUG1200 mice have a phenotype that is milder
than the MBNL1 knockout and HSALR mice [30]. It is also
possible that alternative splicing events in C57BL/6 mice are in
general less sensitive to expression of CUG repeats. SCNM1 is a
disease modifying allele that affects splicing, and that is most
severely affected in C57BL/6 [58,59]. Such strain-specific
differences may produce overlapping but globally distinct splicing
signatures that may contribute to differences in the expression of
the DM1 phenotype in FVB/n and C57BL/6 mice. Because no
animal model reproduces the full pathophysiological manifesta-
tions of the disease, it is therefore of utmost importance to use
human samples to validate data obtained from mouse models with
the goal of uncovering molecular alterations that associate with
core aspects of the pathophysiology.
We identified 50 mis-splicing events in the fetal DM1 myoblast
cell cultures, including events known to be mis-spliced in adult
tissues, such as BIN1, INSR, CLCC1, TTN.a and TTN.b [42].
We also confirmed a known misregulated splicing event at the 39
end of the coding region of DMD (dystrophin), a gene in which
mutations cause Duchenne and Becker muscular dystrophies.
Overall, half of the altered events in embryonic DM1 cells
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occurred in cytoskeleton (21 ASEs) and channel (5 ASEs) genes.
Among the channel genes, the voltage-gated potassium channel
Kv4.3 gene KCND3 produced more of the skipped product both
in embryonic and adult DM1 cells. KCND3 is involved in
neuronal excitability and is a target of the splicing factor
RBFOX1, since inclusion of the 57 nt exon is increased in the
brain of Rbfox12/2 knockout mice [57]. We observed that
human KCND3 splicing remained unchanged when RBFOX1
was knocked down, possibly because the intron upstream of the
alternative exon in human KCND3 lacks the RBFOX binding
element and putative silencer found in the mouse gene at this
position [57].
By profiling splicing in adult DM1 tissues, we noted two known
aberrant mis-splicing events (INSR and TTN.a), but also identified
several new alterations. In addition to KCND3, SYNE1 splicing
was also altered both in embryonic and adult DM1 tissues. SYNE1
(also known as nesprin) is a spectrin-repeat protein that forms a
network that links various subcellular structures throughout the
muscle sarcomere to the actin cytoskeleton. SYNE1 has been
implicated in Emery-Dreifuss muscular dystrophy (muscle wasting
and weakness) [60]. The alternative segment of SYNE1 does not
affect the structure of known protein functional domains; thus the
functional impact of the variant lacking the alternative exon
remains unclear. QKI.a splicing was altered in DM1 patients
(more inclusion). QKI is an RNA binding protein involved in
neuronal function (myelination), blood vessel formation, smooth
muscle formation and heart development. In zebrafish, the loss of
QkA affects fast muscle fiber maturation as well as Hh-induced
muscle derivative specification and/or morphogenesis [61,62].
QKI was recently implicated as a global regulator of splicing
during vertebrate muscle development [63].
Regulatory interactions of MBNL1 and RBFOX1
We sought to gain insights into the regulatory pathways that
yield splicing alterations in fetal and adult human DM1 muscle
tissues. The impact of depleting MBNL1 was evaluated because
the sequestration of MBNL1 by CUG repeats has been associated
with many splicing defects. The depletion of MBNL1 in the
embryonic myoblast culture (HFN) revealed 48 alternative splicing
events sensitive to MBNL1 levels (Table S2, MBNL1 RBFOX1
knockdown tab, and Fig. 4a). Six of these events occurred in
the same direction as in the fetal DM1 lines, and five occurred in
the reverse direction (Fig. 4b).
We also tested the impact of RBFOX1 because it is mis-spliced
in adult DM1 tissues and in DMBNL1 mice [14] to produce a
defective regulator lacking a complete RNA binding motif [54]. A
recent study indicated that the knockdown of Rbfox1 inhibits
muscle differentiation, and that RBFOX1 expression was altered
in a mouse model of facioscapulohumeral muscular dystrophy
[64]. We identified 34 RBFOX1 targets in muscle-relevant genes
(Fig. 4a), seven of which displayed altered splicing in embryonic
and/or adult DM1 samples (Fig. 4b and 4c). Notably, while the
individual depletion of MBNL1 and RBFOX1 respectively
affected the splicing of 29% and 20% of the 163 events tested,
half of the 48 events controlled by MBNL1 were co-regulated by
RBFOX1. In addition to ion channel proteins and components of
the cytoskeleton, the list (Table 1) includes acetylcholine recep-
tors, which in conjunction with integrins, are critical to form
neuromuscular junctions [48]. The MBNL1/RBFOX1 co-regu-
lated genes also include four that were mis-spliced in DM1 tissues
(Fig. 4b and 4c). Knocking down MBNL1 and RBFOX2 in a
cancer cell line revealed a similar convergence of regulation for
muscle-relevant genes since 50% of these genes were co-regulated
by MBNL1 and RBFOX1 (http://palace.lgfus.ca/data/related/
2075). In contrast, only 6% of co-regulation was observed on a
different set of 47 genes implicated in cancer [65]. While MBNL1
and RBFOX1 have been individually implicated in modulating
splicing decisions during muscle and heart development [2,66],
our results suggest that MBNL1 and RBFOX proteins converge to
regulate the splicing of a common subset of genes involved in
muscle function. Recent work suggests that MBNL1 and
RBFOX2 also cooperate to implement a splicing program
associated with the differentiation of human stem cells [67]. It is
therefore intriguing to postulate that a partial loss of MBNL1 and
RBFOX1 activity in both fetal and adult DM1 tissues may
compromise a critical splicing program associated with muscle
differentiation. Given that muscle differentiation occurs in the
damaged skeletal muscle of DM1 mice [49], mis-splicing events in
muscle-relevant genes caused by defective MBNL1 and RBFOX1
activity may compromise tissue regeneration. Lastly, it is
interesting to consider the microtubule-associated protein Tau
(MAPT/Tau) whose splicing is misregulated in DM1 brains
[68,69], a defect that may contribute to neuropsychological
manifestations. MBNL proteins regulate the splicing of tau
alternative exon 2 [70], and we find that ectopic expression of
RBFOX1 can partially repress the splicing aberration of tau exon
2 induced in T98 glioblastoma cells by transfecting the CUG
repeat expression vector DT960 (Fig. S2). Co-regulation of
splicing by MBNL and RBFOX proteins may therefore extend to
neuronal tissues, and their deficient activity in DM1 brains may
lead to aberrant splicing of genes such as tau/MAPT that may then
contribute to cognitive abnormalities.
Overall, our analysis has unveiled a splicing regulatory network
where MBNL1 and RBFOX1 are co-regulating a group of events
that may be relevant to muscle function and development. Since
RBFOX1 most often imposes regulation in the same direction as
MBNL1, the aberrant splicing of RBFOX1 in adult DM1 tissues
may therefore amplify the mis-splicing of ASEs already affected by
the MBNL1 deficiency.
Supporting Information
Figure S1 ASEs that are co-regulated by MBNL1 and
RBFOX1/RBFOX2. A. Immunoblot analysis following the
knockdown of RBFOX1/RBFOX2 and MBNL1 in a HFN cell
culture. A control siRNA (si-C) was also used, and housekeeping
proteins (GAPDH or a-tubulin) were tested as loading controls. B.
Histograms showing splicing changes (DY) observed for ASEs
following MBNL1 (black bars) or RBFOX1/2 (white bars)
knockdown, relative to si-C-treated HFN cells.
(PDF)
Figure S2 RBFOX1 represses the impact of CUG-
repeats on tau splicing in human glioblastoma T98G
cells. T98G cells were transfected with expression vectors for
RBFOX1, CUG-repeats (DT960) or both. Agarose gel of RT-
PCR reactions designed to amplify tau splicing products are
shown on top, and histograms depict exon 2 exclusion level in
percentage with standard deviations. * = p,0.05; ** = p,0.01. In
non-DM1 mimicking conditions, RBFOX1 did not significantly
modify the splicing of tau exon 2. DT960 increased tau exon 2
exclusion, and this effect was partially prevented by co-expressing
RBFOX1.
(PDF)
Table S1 List of ASEs screened in mice. The table lists all
ASEs that were tested for splicing in mouse tissues. For each ASE,
the gene name and primer pair names (Columns A and B) and a
summary description of the type and size of each ASE (Column C)
Splicing Regulation in DM1
PLOS ONE | www.plosone.org 9 September 2014 | Volume 9 | Issue 9 | e107324
is given. Column D provides a comparison of PSI shift direction
between our observations and those reported by Du et al. [14]. p-
values, q-values and |DY| are also provided for the CUG600 and
CUG1200 mice relative to wild type (WT), as well as for the
gastrocnemius and tibialis anterior comparison (Columns E-M).
Tests for threshold levels of p, q and |DY| are reported in
Columns N-AB. Average PSI values and standard deviations are
presented in Columns AC-AH for all tissue groups screened.
Column AI compares hits obtained with data from Du et al. [14].
The portion in yellow corresponds to misregulated events in
CUG1200 with q-values inferior to 0.05 and |DY| superior to 5
percentage points. When more than 1 ASEs originated from one
gene, ASEs were categorized as xxx.a, xxx.b, etc.
(XLSX)
Table S2 List of ASEs screened in DM1 embryonic cell
lines, patient tissues and knockdown assays. The file
includes three sheets that individually list the ASEs screened in
each experiment. DM1 Fetal Cells tab: List of the 487 human
ASEs analyzed. Column A: Gene Name, where more than one
ASE was targeted the suffix.a,.b, … is used. Column B: |DY|
values for ST-3500 (Y values: Column M, standard deviation:
Column N) minus Normal Fetal cells (Y values: Column E,
standard deviation: Column F). Columns C and D: hit in cells (this
sheet) and DM1 tissues (DM1 Tissues sheet) respectively, refer to
text for selection criteria. Fifty cell hits shown in red, tissue hits
shown in yellow and blue (see legend for DM1 Tissues sheet,
below). Columns G-L: Y values and standard deviations for
Normal Adult, ST-750 and ST-1200 cells. Columns O-T:
Calculated p and q values (see text) for Normal Fetal cells (N_F)
compared to ST-750, ST-1200 and ST-3500 cells. Columns U
and V: p and q values for Normal fetal cells compared to all three
DM cell lines combined. Columns W and X: p and q values for
Normal fetal cells compared to Normal Adult (N_A) cells. DM1
Tissues tab: List of the 163 human ASEs analyzed. Column A:
Column A: Gene Name, where more than one ASE was targeted
the suffix.a,.b, … is used. Columns B-D: ASE type and expected
amplicon sizes in base pairs (bp) following PCR amplification of
region flanking ASE. Column E and F: hit in tissues (this sheet)
and cells (DM1 Fetal Cells sheet) respectively, refer to text for
selection criteria. Top ten tissue hits are shown in yellow, and
following 20 hits shown blue. Columns G-I: |DY|, p and q values
for DM1 tissues versus normal controls. Columns J-R:Y values for
individual DM1 and control (CTL) tissues. Column S-V: PCR
primer names and sequences. MBNL1 RBFOX1 Knockdown
tab: List of the 163 human ASEs analyzed (identical to DM1
Tissues). Column A: Gene Name, where more than one ASE was
targeted the suffix.a,.b, … is used. Columns B and C: Hit in tissues
(DM1 Tissues sheet) and cells (DM1 Fetal Cells sheet) respectively,
refer to text for selection criteria. Top ten tissue hits are shown in
yellow, and following 20 hits shown blue, 50 cell hits shown in red.
Columns E-K: |DY| MBNL1 or RBFOX1 knockdown minus
control in HFN and fibroblasts, see text for hit criteria. Columns
L-S: DY data for untreated HFN, mock transfected HFN,
MBNL1 and RBFOX1 knockdown HFN cells and untreated
and knockdown fibroblast cells. Column T: Presence and position
relative to splice site of RBFOX1 binding motif. Negative number
is nucleotide position upstream of 39 splice site, positive number is
position relative to 59 splice site of alternative exon. Column U and
V: Presence, occurrence and position relative to splice sites of
UGC repeats (e.g. 261 refers to two repeats occurring 1 time).
Positions upstream (negative numbers) and downstream (positive
numbers) relative to 39 and 59 splice sites, respectively. qPCR tab:
mRNA expression levels following RNA interference knockdown
of MBNL1 and RBFOX1. Relative expression levels (RE) and
technical error of triplicate qPCR reactions (dT) shown 48h post
transfection for mock transfected HFN cells (HFN CTL-), and
knockdowns (HFN siMBNL, and HFN siRBFOX1). Reference
gene primer sequences are shown. RE and dT calculations
performed using the qBASE package [34].
(XLSX)
Text S1 Supplementary material and methods.
(DOCX)
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